Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):392–398. doi: 10.1054/bjoc.1999.0932

p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy

I Ganly 1,2, D S Soutar 1, R Brown 2, S B Kaye 2
PMCID: PMC2363290  PMID: 10646894

Abstract

The aim of the study was to determine the incidence of p53 alterations by mutation, deletion or inactivation by mdm2 or human papillomavirus (HPV) infection in recurrent squamous cell cancer of the head and neck (SCCHN) refractory to radiotherapy. Twenty-two tumours were studied. The p53 status of each tumour was analysed by sequencing of exons 4–9 and by immunohistochemistry. Mdm2 expression was assessed by immunohistochemistry and HPV infection was assessed by polymerase chain reaction of tumour DNA for HPV 16, 18 and 33. Fifteen (68%) of the 22 tumours studied had p53 mutations, while seven had wild-type p53 sequence. p53 immunohistochemistry correlated with the type of mutation. HPV DNA was detected in 8 (36%) tumours and all were of serotype HPV 16. Of these, five were in tumours with mutant p53 and three were in tumours with wild-type p53. Mdm2 overexpression was detected in 11 (50%) tumours. Of these, seven were in tumours with mutant p53 and four were in tumours with wild-type p53. Overall, 21 of the 22 tumours had p53 alterations either by mutation, deletion or inactivation by mdm2 or HPV. In this study, the overall incidence of p53 inactivation in recurrent head and neck cancer was very high at 95%. The main mechanism of inactivation was gene mutation or deletion which occurred in 15 of the 22 tumours studied. In addition, six of the seven tumours with wild-type p53 sequence had either HPV 16 DNA, overexpression of mdm2 or both which suggested that these tumours had p53 inactivation by these mechanisms. This high incidence of p53 dysfunction is one factor which could account for the poor response of these tumours to radiotherapy and chemotherapy. Therefore, new therapies for recurrent SCCHN which either act in a p53 independent pathway, or which restore p53 function may be beneficial in this disease. © 2000 Cancer Research Campaign

Keywords: p53, HPV, mdm2, head and neck cancer

Full Text

The Full Text of this article is available as a PDF (738.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996 Oct 18;274(5286):373–376. doi: 10.1126/science.274.5286.373. [DOI] [PubMed] [Google Scholar]
  2. Boyle J. O., Hakim J., Koch W., van der Riet P., Hruban R. H., Roa R. A., Correo R., Eby Y. J., Ruppert J. M., Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993 Oct 1;53(19):4477–4480. [PubMed] [Google Scholar]
  3. Brachman D. G., Graves D., Vokes E., Beckett M., Haraf D., Montag A., Dunphy E., Mick R., Yandell D., Weichselbaum R. R. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 1992 Sep 1;52(17):4832–4836. [PubMed] [Google Scholar]
  4. Buttitta F., Marchetti A., Gadducci A., Pellegrini S., Morganti M., Carnicelli V., Cosio S., Gagetti O., Genazzani A. R., Bevilacqua G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997;75(2):230–235. doi: 10.1038/bjc.1997.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Böttger A., Böttger V., Sparks A., Liu W. L., Howard S. F., Lane D. P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997 Nov 1;7(11):860–869. doi: 10.1016/s0960-9822(06)00374-5. [DOI] [PubMed] [Google Scholar]
  6. Catimel G., Verweij J., Mattijssen V., Hanauske A., Piccart M., Wanders J., Franklin H., Le Bail N., Clavel M., Kaye S. B. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994 Jul;5(6):533–537. doi: 10.1093/oxfordjournals.annonc.a058908. [DOI] [PubMed] [Google Scholar]
  7. Chung K. Y., Mukhopadhyay T., Kim J., Casson A., Ro J. Y., Goepfert H., Hong W. K., Roth J. A. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res. 1993 Apr 1;53(7):1676–1683. [PubMed] [Google Scholar]
  8. Clavel M., Vermorken J. B., Cognetti F., Cappelaere P., de Mulder P. H., Schornagel J. H., Tueni E. A., Verweij J., Wildiers J., Clerico M. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521–526. doi: 10.1093/oxfordjournals.annonc.a058906. [DOI] [PubMed] [Google Scholar]
  9. Clayman G. L., el-Naggar A. K., Lippman S. M., Henderson Y. C., Frederick M., Merritt J. A., Zumstein L. A., Timmons T. M., Liu T. J., Ginsberg L. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Jun;16(6):2221–2232. doi: 10.1200/JCO.1998.16.6.2221. [DOI] [PubMed] [Google Scholar]
  10. Clayman G. L., el-Naggar A. K., Roth J. A., Zhang W. W., Goepfert H., Taylor D. L., Liu T. J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995 Jan 1;55(1):1–6. [PubMed] [Google Scholar]
  11. Crook T., Wrede D., Vousden K. H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene. 1991 May;6(5):873–875. [PubMed] [Google Scholar]
  12. Czeglédy J., Iosif C., Hansson B. G., Evander M., Gergely L., Wadell G. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? Int J Cancer. 1995 Jun 22;64(3):211–215. doi: 10.1002/ijc.2910640312. [DOI] [PubMed] [Google Scholar]
  13. Forastiere A. A. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol. 1994 Oct;21(5 Suppl 12):20–27. [PubMed] [Google Scholar]
  14. Girod S. C., Cesarz D., Fischer U., Krueger G. R. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res. 1995 Jul-Aug;15(4):1453–1457. [PubMed] [Google Scholar]
  15. Haraf D. J., Nodzenski E., Brachman D., Mick R., Montag A., Graves D., Vokes E. E., Weichselbaum R. R. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr;2(4):755–762. [PubMed] [Google Scholar]
  16. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997 May 15;387(6630):296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  17. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D. D., Kirn D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997 Jun;3(6):639–645. doi: 10.1038/nm0697-639. [DOI] [PubMed] [Google Scholar]
  18. Huang L. C., Clarkin K. C., Wahl G. M. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4827–4832. doi: 10.1073/pnas.93.10.4827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jones K. R., Lodge-Rigal R. D., Reddick R. L., Tudor G. E., Shockley W. W. Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg. 1992 May;118(5):483–485. doi: 10.1001/archotol.1992.01880050029006. [DOI] [PubMed] [Google Scholar]
  20. Kao C. C., Yew P. R., Berk A. J. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology. 1990 Dec;179(2):806–814. doi: 10.1016/0042-6822(90)90148-k. [DOI] [PubMed] [Google Scholar]
  21. Koh J. Y., Cho N. P., Kong G., Lee J. D., Yoon K. p53 mutations and human papillomavirus DNA in oral squamous cell carcinoma: correlation with apoptosis. Br J Cancer. 1998 Aug;78(3):354–359. doi: 10.1038/bjc.1998.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lechner M. S., Mack D. H., Finicle A. B., Crook T., Vousden K. H., Laimins L. A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 1992 Aug;11(8):3045–3052. doi: 10.1002/j.1460-2075.1992.tb05375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Levine A. J. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology. 1990 Aug;177(2):419–426. doi: 10.1016/0042-6822(90)90505-l. [DOI] [PubMed] [Google Scholar]
  24. Liu T. J., Zhang W. W., Taylor D. L., Roth J. A., Goepfert H., Clayman G. L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994 Jul 15;54(14):3662–3667. [PubMed] [Google Scholar]
  25. Mao E. J., Schwartz S. M., Daling J. R., Oda D., Tickman L., Beckmann A. M. Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Int J Cancer. 1996 Apr 22;69(2):152–158. doi: 10.1002/(SICI)1097-0215(19960422)69:2<152::AID-IJC15>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  26. Matsumura T., Yoshihama Y., Kimura T., Shintani S., Alcalde R. E. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology. 1996 Jul-Aug;53(4):308–312. doi: 10.1159/000227578. [DOI] [PubMed] [Google Scholar]
  27. McIlwrath A. J., Vasey P. A., Ross G. M., Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994 Jul 15;54(14):3718–3722. [PubMed] [Google Scholar]
  28. McKaig R. G., Baric R. S., Olshan A. F. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck. 1998 May;20(3):250–265. doi: 10.1002/(sici)1097-0347(199805)20:3<250::aid-hed11>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  29. Miguel R. E., Villa L. L., Cordeiro A. C., Prado J. C., Sobrinho J. S., Kowalski L. P. Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Am J Surg. 1998 Nov;176(5):428–429. doi: 10.1016/s0002-9610(98)00246-3. [DOI] [PubMed] [Google Scholar]
  30. Nabel G. J., Nabel E. G., Yang Z. Y., Fox B. A., Plautz G. E., Gao X., Huang L., Shu S., Gordon D., Chang A. E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307–11311. doi: 10.1073/pnas.90.23.11307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nickers P., Kunkler I., Scalliet P. Modern brachytherapy: current state and future prospects. Eur J Cancer. 1997 Oct;33(11):1747–1751. doi: 10.1016/s0959-8049(97)00300-6. [DOI] [PubMed] [Google Scholar]
  32. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992 Jul 2;358(6381):80–83. doi: 10.1038/358080a0. [DOI] [PubMed] [Google Scholar]
  33. Olshan A. F., Weissler M. C., Pei H., Conway K. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):499–504. [PubMed] [Google Scholar]
  34. Park D. J., Wilczynski S. P., Paquette R. L., Miller C. W., Koeffler H. P. p53 mutations in HPV-negative cervical carcinoma. Oncogene. 1994 Jan;9(1):205–210. [PubMed] [Google Scholar]
  35. Paz I. B., Cook N., Odom-Maryon T., Xie Y., Wilczynski S. P. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997 Feb 1;79(3):595–604. doi: 10.1002/(sici)1097-0142(19970201)79:3<595::aid-cncr24>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  36. Pruneri G., Pignataro L., Carboni N., Luminari S., Capaccio P., Neri A., Buffa R. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Mod Pathol. 1997 Aug;10(8):785–792. [PubMed] [Google Scholar]
  37. Righetti S. C., Della Torre G., Pilotti S., Ménard S., Ottone F., Colnaghi M. I., Pierotti M. A., Lavarino C., Cornarotti M., Oriana S. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996 Feb 15;56(4):689–693. [PubMed] [Google Scholar]
  38. Roth J. A., Nguyen D., Lawrence D. D., Kemp B. L., Carrasco C. H., Ferson D. Z., Hong W. K., Komaki R., Lee J. J., Nesbitt J. C. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996 Sep;2(9):985–991. doi: 10.1038/nm0996-985. [DOI] [PubMed] [Google Scholar]
  39. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8. [DOI] [PubMed] [Google Scholar]
  40. Stoler M. H., Rhodes C. R., Whitbeck A., Wolinsky S. M., Chow L. T., Broker T. R. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol. 1992 Feb;23(2):117–128. doi: 10.1016/0046-8177(92)90232-r. [DOI] [PubMed] [Google Scholar]
  41. Yeudall W. A., Campo M. S. Human papillomavirus DNA in biopsies of oral tissues. J Gen Virol. 1991 Jan;72(Pt 1):173–176. doi: 10.1099/0022-1317-72-1-173. [DOI] [PubMed] [Google Scholar]
  42. Yoshikawa H., Kawana T., Kitagawa K., Mizuno M., Yoshikura H., Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res. 1991 May;82(5):524–531. doi: 10.1111/j.1349-7006.1991.tb01882.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131–156. doi: 10.1007/978-3-642-78487-3_8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES